title: Second allogeneic transplants for leukemia using blood instead of bone marrow as a source of hemopoietic cells.
abstract: There is increasing interest in blood cell transplants (BCT) from normal donors as an alternative to BMT. Ten patients with relapsed or persistent leukemia after BMT received intensive cytotoxic conditioning followed by allogeneic BCT. Three BCT were from single-antigen mismatched donors; two of the corresponding recipients had rejected a BMT from the same donor. Two patients received BCT from a different donor (one matched, one single-antigen mismatched). The other six BCT were from the same, fully matched, bone marrow donors. Donors were given G-CSF to mobilize progenitor cells which were collected by a single 2-4 h leukapheresis. Methotrexate, CsA and folinic acid were used for GVHD prophylaxis for all transplants but CsA was discontinued sooner after BCT than after BMT. One patient died without engraftment having rejected a BMT from the same single-antigen mismatched donor 4 years previously. Nine patients had granulocyte recovery at a median of 14 days, up to 6 days faster than with their previous BMT. Platelet recovery was also 2-6 days faster than with BMT in four previously engrafting patients. Four patients died without platelet recovery after BCT within a year of BMT, three of treatment-related toxicity and one of relapse. Two patients developed grade II acute GVHD. Of six patients given BCT more than a year from BMT, four, all with acute leukemia, survive 7, 14, 29 and 29 months after BCT and one relapsed at 7 months. All four survivors developed chronic GVHD. These results indicate that BCT may be useful therapy for relapse occurring more than a year after BMT.
authors.affiliation: Alberta Bone Marrow Transplant Program, Foothills Hospital, Edmonton, Canada.
authors.forename: J A
authors.initials: JA
authors.lastname: Russell
authors.forename: T
authors.initials: T
authors.lastname: Bowen
authors.forename: C
authors.initials: C
authors.lastname: Brown
authors.forename: J
authors.initials: J
authors.lastname: Luider
authors.forename: J D
authors.initials: JD
authors.lastname: Ruether
authors.forename: D
authors.initials: D
authors.lastname: Stewart
authors.forename: K
authors.initials: K
authors.lastname: Jorgenson
authors.forename: M J
authors.initials: MJ
authors.lastname: Coppes
authors.forename: A R
authors.initials: AR
authors.lastname: Turner
authors.forename: L
authors.initials: L
authors.lastname: Larratt
authors.forename: A
authors.initials: A
authors.lastname: Chaudhry
authors.forename: K
authors.initials: K
authors.lastname: Booth
authors.forename: M C
authors.initials: MC
authors.lastname: Poon
authors.forename: J
authors.initials: J
authors.lastname: Klassen
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007938:Leukemia / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D014184:Transplantation, Homologous